155 related articles for article (PubMed ID: 25979262)
1. Variability in Expression of CYP3A5 in Human Fetal Liver.
Vyhlidal CA; Pearce RE; Gaedigk R; Calamia JC; Shuster DL; Thummel KE; Leeder JS
Drug Metab Dispos; 2015 Aug; 43(8):1286-93. PubMed ID: 25979262
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
3. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers.
Hakkola J; Raunio H; Purkunen R; Saarikoski S; Vähäkangas K; Pelkonen O; Edwards RJ; Boobis AR; Pasanen M
Biol Neonate; 2001; 80(3):193-201. PubMed ID: 11585982
[TBL] [Abstract][Full Text] [Related]
5. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Hall SD; Jones DR; VandenBranden M; Wrighton SA
Biochem Pharmacol; 1994 Apr; 47(9):1643-53. PubMed ID: 8185679
[TBL] [Abstract][Full Text] [Related]
6. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
7. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.
Lin YS; Dowling AL; Quigley SD; Farin FM; Zhang J; Lamba J; Schuetz EG; Thummel KE
Mol Pharmacol; 2002 Jul; 62(1):162-72. PubMed ID: 12065767
[TBL] [Abstract][Full Text] [Related]
8. Variability of CYP3A7 expression in human fetal liver.
Leeder JS; Gaedigk R; Marcucci KA; Gaedigk A; Vyhlidal CA; Schindel BP; Pearce RE
J Pharmacol Exp Ther; 2005 Aug; 314(2):626-35. PubMed ID: 15845858
[TBL] [Abstract][Full Text] [Related]
9. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes.
Quintieri L; Palatini P; Nassi A; Ruzza P; Floreani M
Biochem Pharmacol; 2008 Mar; 75(6):1426-37. PubMed ID: 18191104
[TBL] [Abstract][Full Text] [Related]
10. The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells.
Knops N; van den Heuvel LP; Masereeuw R; Bongaers I; de Loor H; Levtchenko E; Kuypers D
Mol Pharm; 2015 Mar; 12(3):758-68. PubMed ID: 25590378
[TBL] [Abstract][Full Text] [Related]
11. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
[TBL] [Abstract][Full Text] [Related]
12. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
13. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
Warrington JS; Poku JW; von Moltke LL; Shader RI; Harmatz JS; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Mar; 292(3):1024-31. PubMed ID: 10688619
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.
Westlind-Johnsson A; Malmebo S; Johansson A; Otter C; Andersson TB; Johansson I; Edwards RJ; Boobis AR; Ingelman-Sundberg M
Drug Metab Dispos; 2003 Jun; 31(6):755-61. PubMed ID: 12756208
[TBL] [Abstract][Full Text] [Related]
15. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.
Thummel KE; Shen DD; Podoll TD; Kunze KL; Trager WF; Bacchi CE; Marsh CL; McVicar JP; Barr DM; Perkins JD
J Pharmacol Exp Ther; 1994 Oct; 271(1):557-66. PubMed ID: 7965756
[TBL] [Abstract][Full Text] [Related]
16. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
Huang W; Lin YS; McConn DJ; Calamia JC; Totah RA; Isoherranen N; Glodowski M; Thummel KE
Drug Metab Dispos; 2004 Dec; 32(12):1434-45. PubMed ID: 15383492
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes.
Dennison JB; Jones DR; Renbarger JL; Hall SD
J Pharmacol Exp Ther; 2007 May; 321(2):553-63. PubMed ID: 17272675
[TBL] [Abstract][Full Text] [Related]
18. Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta.
Schuetz JD; Kauma S; Guzelian PS
J Clin Invest; 1993 Aug; 92(2):1018-24. PubMed ID: 8349787
[TBL] [Abstract][Full Text] [Related]
19. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.
Patki KC; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2003 Jul; 31(7):938-44. PubMed ID: 12814972
[TBL] [Abstract][Full Text] [Related]
20. CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity.
Christensen H; Hestad AL; Molden E; Mathiesen L
Xenobiotica; 2011 Jan; 41(1):1-5. PubMed ID: 20954901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]